Hyperion DeFi, Inc.

NasdaqCM:HYPD Stock Report

Market Cap: US$29.2m

Hyperion DeFi Valuation

Is HYPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of HYPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate HYPD's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate HYPD's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HYPD?

Key metric: As HYPD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HYPD. This is calculated by dividing HYPD's market cap by their current revenue.
What is HYPD's PS Ratio?
PS Ratio35.9x
SalesUS$813.46k
Market CapUS$29.19m

Price to Sales Ratio vs Peers

How does HYPD's PS Ratio compare to its peers?

The above table shows the PS ratio for HYPD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average29x
CTXR Citius Pharmaceuticals
4.8x37.88%US$19.1m
NRXP NRx Pharmaceuticals
59.3x47.86%US$72.7m
RANI Rani Therapeutics Holdings
51.3x61.39%US$83.7m
ETST Earth Science Tech
0.7x18.83%US$25.3m
HYPD Hyperion DeFi
35.9x67.63%US$29.2m

Price-To-Sales vs Peers: HYPD is expensive based on its Price-To-Sales Ratio (35.9x) compared to the peer average (29x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does HYPD's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

81 CompaniesPrice / SalesEstimated GrowthMarket Cap
VTRS Viatris
1.1x2.88%US$15.47b
AMRX Amneal Pharmaceuticals
1.3x4.96%US$3.98b
PAHC Phibro Animal Health
1.5x3.43%US$2.25b
BHC Bausch Health Companies
0.2x-1.59%US$1.98b
HYPD 35.9xIndustry Avg. 4.6xNo. of Companies81PS0816243240+
81 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HYPD is expensive based on its Price-To-Sales Ratio (35.9x) compared to the US Pharmaceuticals industry average (4.6x).

Price to Sales Ratio vs Fair Ratio

What is HYPD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HYPD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio35.9x
Fair PS Ratio11.7x

Price-To-Sales vs Fair Ratio: HYPD is expensive based on its Price-To-Sales Ratio (35.9x) compared to the estimated Fair Price-To-Sales Ratio (11.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HYPD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.25
US$6.28
+93.08%
31.47%US$8.25US$4.30n/a2
Mar ’27US$2.82
US$5.88
+108.33%
31.91%US$7.75US$4.00n/a2
Feb ’27US$3.52
US$5.88
+66.90%
31.91%US$7.75US$4.00n/a2
Jan ’27US$3.56
US$5.88
+65.03%
31.91%US$7.75US$4.00n/a2
Dec ’25US$7.92
US$280.00
+3,435.35%
42.86%US$400.00US$160.00US$3.702
Nov ’25US$40.72
US$580.00
+1,324.36%
40.65%US$960.00US$320.00US$6.484
Oct ’25US$40.38
US$580.00
+1,336.50%
40.65%US$960.00US$320.00US$9.944
Sep ’25US$44.01
US$613.33
+1,293.69%
43.04%US$960.00US$320.00US$6.103
Aug ’25US$93.60
US$720.00
+669.23%
27.22%US$960.00US$480.00US$7.083
Jul ’25US$54.31
US$720.00
+1,225.67%
27.22%US$960.00US$480.00US$10.563
Jun ’25US$64.64
US$720.00
+1,013.86%
27.22%US$960.00US$480.00US$1.673
May ’25US$73.20
US$746.67
+920.04%
26.73%US$960.00US$480.00US$1.153
Apr ’25US$78.68
US$746.67
+848.99%
26.73%US$960.00US$480.00US$1.133
US$6.28
Fair Value
48.2% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/05 12:32
End of Day Share Price 2026/04/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hyperion DeFi, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brett KnoblauchCantor Fitzgerald & Co.
James McIlreeChardan Capital Markets, LLC
Timothy ChiangNorthland Capital Markets